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Inappropriate p53 activation during development
induces features of CHARGE syndrome
Jeanine L. Van Nostrand1, Colleen A. Brady1{, Heiyoun Jung1, Daniel R. Fuentes2, Margaret M. Kozak1{, Thomas M. Johnson1{,
Chieh-Yu Lin3, Chien-Jung Lin4, Donald L. Swiderski5, Hannes Vogel3, Jonathan A. Bernstein6, Tania Attie´-Bitach7,8,
Ching-Pin Chang9, Joanna Wysocka2,4, Donna M. Martin10,11 & Laura D. Attardi1,12
CHARGEsyndrome is amultiple anomalydisorder inwhichpatients
presentwithavarietyofphenotypes, includingocular coloboma,heart
defects, choanal atresia, retardedgrowthanddevelopment, genitouri-
naryhypoplasia andearabnormalities1.Despite 70–90%ofCHARGE
syndrome cases resulting frommutations in the geneCHD7, which
encodes anATP-dependent chromatin remodeller, the pathwaysun-
derlying thediversephenotypes remainpoorlyunderstood2. Surpris-
ingly, our studiesof a knock-inmutantmouse strain that expresses a
stabilizedandtranscriptionallydeadvariantof the tumour-suppressor
protein p53 (p5325,26,53,54)3, alongwith awild-type allele of p53 (also
knownasTrp53), revealed late-gestational embryonic lethality asso-
ciated with a host of phenotypes that are characteristic of CHARGE
syndrome, including coloboma, inner andouter earmalformations,
heart outflow tract defects and craniofacial defects. We found that
the p5325,26,53,54mutant protein stabilized and hyperactivated wild-
type p53, which then inappropriately induced its target genes and
triggered cell-cycle arrest or apoptosis during development. Impor-
tantly, thesephenotypeswereonlyobservedwithawild-typep53allele,
as p5325,26,53,54/2 embryoswere fully viable. Furthermore,we found
that CHD7 can bind to the p53 promoter, thereby negatively regu-
latingp53 expression, and thatCHD7 loss inmouseneural crest cells
or samples from patients with CHARGE syndrome results in p53
activation. Strikingly,we found thatp53heterozygositypartially res-
cued the phenotypes in Chd7-null mouse embryos, demonstrating
that p53 contributes to the phenotypes that result fromCHD7 loss.
Thus, inappropriatep53activationduringdevelopment canpromote
CHARGEphenotypes, supporting the idea that p53 has a critical role
in developmental syndromes and providing important insight into
the mechanisms underlying CHARGE syndrome.
Unrestrained p53 activity induced by loss of the negative regulators
MDM2orMDM4causes early embryonic lethality4. To explore the role
of transcriptional activation by p53 in promoting developmental fail-
ure, we examined embryonic development in knock-in mice carrying
mutations inoneor bothof p53’s two transcriptional activationdomains
(p5325,26 andp5325,26,53,54; Fig. 1a andExtendedDataFig. 1). Thesemu-
tations both disrupt the p53–MDM2 interaction—recapitulating loss
of MDM2 regulation—and compromise transactivation3. Expression
of p5325,26, whose ability to transactivate most (but not all) p53 target
genes is severely impaired, caused early embryonic lethality5 (at embry-
onic day (E) 10.5; ExtendedData Fig. 2a–c). Surprisingly, p5325,26,53,54/1
embryos (p5325,26,53,54 is transactivationdead) also exhibited embryonic
lethality but between E13.5 and E15.5 (ExtendedData Tables 1 and 2).
Lethality associated with p5325,26,53,54 depended on the presence of a
wild-type p53 allele, as p5325,26,53,54/2 adultmice were viable (Extended
DataFig. 2b,d).This observation is incontrast to theembryonic lethality
ofp5325,26/2mice,whichprobably results fromtheresidual transactivation
potential of p5325,26 on genes such as Bax3 (Extended Data Fig. 2a, b).
Our findings underscore the importance of transactivation for the
embryonic lethality induced by stabilized p53 (because p5325,26,53,54/2
mice are viable), as well as revealing an intriguing genetic interaction
between p5325,26,53,54 (which is transactivation dead) andwild-type p53
during development.
Analysis of p5325,26,53,54/1 embryos identified numerous gender-
independent developmental phenotypes that were absent in littermate
controls (Figs 1 and 2 andExtendedData Figs 3 and 4). E13.5 and older
p5325,26,53,54/1 embryos commonlydisplayed exencephaly, aswell as cra-
niofacial defects, including square-shaped faces, short lower jaws, cleft
lip and cleft palate (Fig. 1b, c and Extended Data Fig. 4a, b). Further-
more, p5325,26,53,54/1 embryos displayed defects in external ear forma-
tion (Fig. 1d) and a spectrum of inner ear defects, ranging from mild
(for example, the posterior semi-circular canal (SCC) was either trun-
cated or fused to the common crus (Fig. 1e)) to highly abnormal (for
example, extreme inner ear bonemalformation).We also observed ret-
inal coloboma inp5325,26,53,54/1 embryos (Fig. 1f, g). As a potential con-
tributor to the craniofacial defects, we examined osteogenesis6 and
found delayed bone formation in p5325,26,53,54/1 embryos, suggesting
growth retardation (ExtendedData Fig. 4c). Notably, this constellation
of phenotypes is reminiscent of those in human CHARGE syndrome.
In particular, the combined presentation of coloboma and inner ear
defects is characteristic ofCHARGEsyndromeand rarely occurs inother
conditions7.
Given this phenotypic overlap with CHARGE syndrome, we exam-
inedwhetherp5325,26,53,54/1 embryosdisplayotherCHARGE-associated
characteristics8–10. The hearts in p5325,26,53,54/1 embryos possessed the
full complement of cell types (ExtendedDataFig. 4d) but displayed out-
flow tract defects (for example, persistent truncus arteriosus anddouble
outlet right ventricle; Fig. 2a andExtendedData Fig. 4e, f) accompanied
by ventricular septation defects (data not shown). The atrioventricular
cushions also failed to undergo remodelling, foreshadowing potential
heart valve defects (Fig. 2b andExtendedData Fig. 4f).Notably, outflow
tract and atrioventricular septation defects are highly overrepresented
in patients with CHARGE syndrome compared with individuals with
isolated congenital heart disease11. Additionally, the kidneys and thymi
in p5325,26,53,54/1 embryos were smaller than those in controls, and the
kidneys displayedbranching defects (Fig. 2c andExtendedDataFig. 4g).
These phenotypeswere in contrast to the liver, which exhibited normal
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Figure 1 | p5325,26,53,54/1 embryos exhibit
lethality and diverse craniofacial defects
characteristic of CHARGE syndrome. a, Top,
p53 transcriptional activation domain (TAD)
mutant protein with Leu25Gln, Trp26Ser,
Phe53Gln, Phe54Ser mutations. Centre and
bottom,Credeletes the lox–Stop–lox (LSL) cassette,
inducing p5325,26,53,54 allele expression. Numbers
in p53 locus schematic indicate exons. Asterisks
denote mutations. PuroR, puromycin resistance.
b, Exencephaly (63%, n5 35; arrow) and short
lower jaw (74%, n5 27; arrowhead) in an E15.5
p5325,26,53,54/1 embryo. Original magnification,
36.3. c, Cleft palate (arrow) in an E15.5
p5325,26,53,54/1 embryo (n5 3). Original
magnification, 3100. d, Absent external ear pinna
(arrow) in an E15.5 p5325,26,53,54/1 embryo. (47%,
n5 17). Original magnification, 340. e, Posterior
semi-circular canal (pc) fused to the common crus
(CC) (71%, n5 12; arrow) in the inner ear of an
E13.5 p5325,26,53,54/1 embryo. ac, anterior canal;
lc, lateral canal. Original magnification, 320.
f, Coloboma (arrow) in an E13.5 p5325,26,53,54/1
embryo (59%, n5 17). Original magnification,
320. g, Retinal coloboma (arrow) in an E15.5
p5325,26,53,54/1 embryo. Re, retina. Original
magnification, 3100.
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Figure 2 | p5325,26,53,54/1 embryos exhibit
additional features of CHARGE syndrome and
p53-dependent cellular responses. a, Double
outlet right ventricle (DORV) in an E13.5
p5325,26,53,54/1 heart (50%, n5 6). Top, The main
pulmonary artery (MPA) connects via the
pulmonary valve (PV) to the right ventricle (RV) in
both the control and p5325,26,53,54/1 embryos.
Bottom, The aorta (Ao) in the control embryo
connects to the left ventricle (LV) via the aortic valve
(AV) (W). The aorta in the p5325,26,53,54/1 embryo
connects to the RV via the AV (*). Original
magnification, 3100. b, Abnormal atrioventricular
cushions in an E13.5 p5325,26,53,54/1 heart (75%,
n5 4) fail to elongate into mature mitral (mv,
arrowhead) and tricuspid (tv, arrow) valves. LA, left
atrium; RA, right atrium. Original magnification,
3100. c, E13.5 p5325,26,53,54/1 kidneys are smaller
(79%), with fewer glomeruli (arrow) on average
than controls (13 glomeruli on average in controls
versus 3 glomeruli on average in mutants; n5 5).
Original magnification, 3200. d, p5325,26,53,54/1
embryonic phenotypes observed in CHARGE
syndrome (1, present; 2, absent). e, Left, Cleaved
caspase 3 (CC3, top) and p53 (bottom)
immunohistochemistry in E15.5 retinas. Arrows
denote CC3-positive cells. Right, The number of
CC3-positive cells per retinal area is shown.
***, P value5 0.007, one-tailed Welch’s t-test
(n5 5). Original magnification, 3400. f, 5-
Bromodeoxyuridine (BrdU) immunofluorescence
in E9.5 PAX3-positive neural crest cells (NCCs)
(delineated by the green dotted line) (see Extended
Data Fig. 6c). Right, The percentage of BrdU-
positive cells in the total PAX31 NCC population
***, P value5 0.004, one-tailed Student’s t-test
(n5 4). Original magnification, 3200.
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architecture andhaematopoiesis (ExtendedData Fig. 4h). Evaluation for
choanal atresiaandexternalgenitaldefects,whichare featuresofCHARGE
syndrome,was precludedby late-gestational embryonic lethality. Impor-
tantly, p53-null embryos did not display CHARGE-like phenotypes,
suggesting that these phenotypes result from p53 activation12–14 (Ex-
tendedData Fig. 5). Collectively, the analysis of p5325,26,53,54/1 embry-
onic phenotypes revealed a strong similarity to phenotypes in patients
with CHARGE syndrome (Fig. 2d and Extended Data Fig. 4i), includ-
ing the presence of hallmarks such as coloboma, earmalformations and
heart defects.Additionally,weobserved exencephaly and late-gestational
lethality, neither ofwhich is commonly reported inCHARGEsyndrome.
However, it remains possible that fetuseswithmore severe phenotypes
of CHARGE syndrome die in utero15,16.
Tounderstand the underlying cellular basis of the p5325,26,53,54/1 em-
bryonic phenotypes, we examined whether p53 induced apoptosis or
cell-cycle arrest in these embryos.Analysis of the retina,which is affected
in coloboma, andNCCs,which are responsible for someCHARGEphe-
notypes, revealedmoreapoptosisand lessproliferation inp5325,26,53,54/1em-
bryos than in littermate controls (Fig. 2e, f andExtendedDataFig. 6a, c, d).
Similar resultswere observed in other tissues affected inCHARGEsyn-
drome, including the thymus,neuroepitheliumandoticvesicles (Extended
Data Fig. 6b, e, f). Thus, both increased apoptosis and reduced prolif-
eration contribute to the p5325,26,53,54/1 embryonic phenotypes.
Wenext investigated themolecularmechanismsbywhichp5325,26,53,54
triggers CHARGE-associated phenotypes.Mutation of p53 residues 25
and 26 inhibits MDM2 interaction, resulting in inappropriate stabil-
ization of the p5325,26,53,54 protein, as seen in untreated p5325,26,53,54/1
andp5325,26,53,54/2mouse embryonic fibroblasts (MEFs) comparedwith
untreated p531/2 MEFs (Fig. 3a and ExtendedData Fig. 7a). Using co-
transfection and co-immunoprecipitation, we found that p5325,26,53,54
interacts withwild-type p53 (Fig. 3b andExtendedData Fig. 7b).More-
over, overexpressing increasing amounts of Flag–p5325,26,53,54 (lanes
2–4), but not Flag–p53 (lanes 6–8), caused haemagglutinin (HA)–p53
protein accumulation (Fig. 3c). Similarly, immunoblot analysis with a
wild-type p53-specific antibody revealed that untreated p5325,26,53,54/1
MEFs containedmorewild-typep53protein (lane 5) thandid untreated
p531/2 or p531/1MEFs (lanes 2 and 3; Fig. 3a). To examine the effects
of increased wild-type p53 abundance, we examined p53 target gene
expression in p5325,26,53,54/1 and controlMEFs. p5325,26,53,54 alone dis-
played no transcriptional activity, as seen in genome-wide microarray
analyses3 (ExtendedData Fig. 7c) and individual gene quantitative PCR
with reverse transcription (qRT–PCR) assays comparingp5325,26,53,54/2
and p532/2 MEFs (Fig. 3d). By contrast, p5325,26,53,54 combined with
wild-type p53 drove elevated expression of certain p53 target genes, in-
cludingNoxa (alsoknownasPmaip1) andPidd, but notp21 (alsoknown
as Cdkn1a) and Mdm2, relative to the levels in p531/2 and p531/1
MEFs, suggesting that p5325,26,53,54 activates wild-type p53 to induce
the expression of specific p53 target genes (Fig. 3d and Extended Data
Fig. 7d). Similarly, overexpression of p5325,26,53,54, but not wild-type
p53, in p531/1 MEFs significantly enhanced the expression of certain
p53 target genes (Extended Data Fig. 7e). Quantitative chromatin im-
munoprecipitation (ChIP) analyses revealed that this selective target
gene activation resulted from greater binding of p53 to the response
elements of particular target genes inp5325,26,53,54/1MEFs than inp531/2
MEFs (Fig. 3e). This pattern probably reflects different affinities of
p53-binding sites for p53 such that p53 can only bind to, and activate
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Figure 3 | p5325,26,53,54 interacts with
and increases wild-type p53 levels and activity.
a, Immunoblot for total p53 (top row) and
wild-type (WT) p53 (second row) in untreated and
doxorubicin (Dox)-treated MEFs of the indicated
genotypes. b-Actin was used as a loading control.
b, Anti-Flag immunoprecipitation (IP) and
immunoblot of p532/2 MEFs transiently
overexpressing HA–p53 and Flag–p53 or Flag–
p5325,26,53,54. The negative controls were HA–MBP
and Flag–enhanced GFP (eGFP). (See also
Extended Data Fig. 7b.) c, Top, Immunoblot of
p532/2 MEFs transiently overexpressing HA–p53
and increasing amounts of Flag–p53 or Flag–
p5325,26,53,54. Bottom, Mean6 s.d. HA–p53
protein levels relative to lane 1 and normalized to
b-actin (n5 3). d, p53 target gene expression in
untreated MEFs of the indicated genotypes,
presented as mean6 s.d. normalized to b-actin
gene expression (n5 4). *, P, 0.05;
***, P, 0.005, p5325,26,53,54/1 versus p531/2MEFs
by two-tailed Student’s t-test. e, Representative
analysis from duplicate p53 ChIP analyses of p53
target genes in MEFs of the indicated genotypes
relative to input DNA. f, Proposed model for how
p5325,26,53,54 affects p53 activity.
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transcription from, lower affinity p53-binding sites (such as those in
Noxa and Pidd) when sufficiently stabilized, as is the case in the pres-
ence of bothp5325,26,53,54 andwild-typep53 (ref. 17). Collectively, these
findings suggest that in p5325,26,53,54/1 embryos, p5325,26,53,54 interacts
with and stabilizeswild-type p53, probably by compromising the inter-
action of p53withMDM2, causing p53 to inappropriately induce target
gene expression, cell-cycle arrest and/or apoptosis, andCHARGE-like
phenotypes (Fig. 3f).
These observations suggested that p53 may respond to CHD7 defi-
ciency andplay a role inCHARGEsyndrome.Analysis ofChd7 expres-
sion levels in p531/2 and p5325,26,53,54/1 MEFs revealed no significant
difference, suggesting that altered Chd7 levels do not underlie the
CHARGE-like phenotypes in p5325,26,53,54/1 embryos (Extended Data
Fig. 8a). We next assessed whether p53 responds to changes in CHD7
status15,16,18,19. Indeed, p53 and certain p53 target genes were induced
in Chd7-null NCCs (Fig. 4a and Extended Data Fig. 8b). Interestingly,
ChIP analyses showed that CHD7 binds to the p53 promoter inNCCs,
suggesting thatCHD7negatively regulates p53 expression, providing a
mechanism by which CHD7 loss might contribute to a p53 response
(Fig. 4b), although not excluding the possibility that CHD7 deficiency
could also activate p53 through other mechanisms. To directly assess
p53 activation in CHARGE syndrome, we analysed CHD7-mutation-
positive fibroblasts frompatients withCHARGE syndrome and found
higher basal p53protein levels than in controls, aswell as p53 target gene
induction, followingmild stress (Fig. 4c, d). Similarly, analysis of thymi
showedmore p53-positive thymocytes inCHD7-mutation-positive fe-
tuseswithCHARGEsyndrome than inunaffected fetuses (Fig. 4e). Thus,
p53 is activated in Chd7-null NCCs and in fibroblasts and tissue from
patients with CHARGE syndrome. To establish the role of p53 down-
stream of Chd7 loss, we tested whether Chd7-null phenotypes are res-
cued by p53heterozygosity.We found that the characteristicChd7-null
phenotypes of severe developmental delay and generalized hypoplasia
at E10.5 are significantly rescued on a p531/2 background. Specifically,
heart development and somite number, an indicator of developmental
stage, are rescued, while limb, forebrain and facial morphogenesis are
partially rescued (Fig. 4f, g andExtendedData Fig. 8c, d). Thus,p53het-
erozygosity rescues phenotypes caused byCHD7 inactivation, although
incompletely,which is consistentwith the existenceofbothp53-dependent
andp53-independent responses downstreamofCHD7 loss.Collectively,
these findings demonstrate that CHD7 deficiency triggers p53 activa-
tion and p53-dependent phenotypes.
Our p5325,26,53,54/1 mouse strain provides a new model with which
to study features that are relevant to CHARGE syndrome.Mousemod-
els of CHARGE syndrome have been generated previously by usingN-
ethyl-N-nitrosourea (ENU)mutagenesisorby targeting theChd7 locus20,21.
WhileChd72/2mutants display embryonic lethality at approximately
E10.5,Chd71/2 mutants are viable, exhibiting defects of the inner ear,
heart, external genitalia andchoanae/palate20,21. In the inner ear,Chd71/2
mice display truncated lateral SCCs and variably truncated posterior
SCCs20,22, whereas p5325,26,53,54/1 embryos primarily exhibit posterior
SCC defects or defects in all three SCCs, similarly to patients with
CHARGE syndrome, in which all three SCCs are often involved23. In-
terestingly,Chd71/2micehavenotbeenreported todisplay theCHARGE
hallmarks of coloboma or cardiac outflow tract defects. Thus, the pres-
enceof extensive ear defects, heart defects andcoloboma inp5325,26,53,54/1
embryos highlights the utility of our model for recapitulating a broader
formofCHARGE syndrome, potentially representing a phenotype that
is intermediate in severity between Chd71/2 and Chd72/2 mutants.
Interestingly, the set of phenotypes of p5325,26,53,54/1 embryos is one
set in a spectrum ofmousemodels whereby varying levels of p53 activ-
ity trigger different phenotypes. UnlikeMdm2 deficiency, which results
in stabilized, fully active wild-type p53, the combination of wild-type
p53 and p5325,26,53,54 in p5325,26,53,54/1 embryos results in modest p53
activation, causing lethality and phenotypes less severe than Mdm2
loss24. The p5325,26,53,54/1 embryonic phenotypes are also in contrast
to those seen in other hyperactive p53 mouse models, including one
model inwhich the expressionof a carboxy-terminalp53 fragment causes
premature ageing andanothermodel inwhich reducedMDM2express-
ion triggers lymphopaenia and reduced body weight in adults25–27. In
these models, the phenotypes manifested without enhanced basal p53
activity or increased p53 stabilization, respectively, potentially explain-
ing the lack of embryonic lethality and themilder phenotypes than ob-
served for p5325,26,53,54/1 embryos.
Mechanistically, our observation that p53 activation is sufficient to
cause CHARGE-like phenotypes in mice suggested that activated p53
could similarly promote the characteristic defects present in human
CHARGE syndrome. Indeed, p53 expression and activity are increased
in thepresenceofCHD7deficiency, andphenotypes triggered byCHD7
loss are partially rescued by p53 heterozygosity. This finding is in con-
trast to a study in which p53 morpholinos failed to rescue Chd7 defi-
ciency in zebrafish, perhaps reflecting species-specific differences28. p53
may also function independently of CHD7 to induce the features of
CHARGE syndrome, a possibility that is relevant in the,10–30% of
CHARGE cases in which CHD7 is not mutated. p53 could become
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Figure 4 | p53 is activated upon CHD7 deficiency and contributes to Chd7-
null phenotypes. a, p53 target gene expression inChd71/1 andChd72/2 (whi/
whi) NCCs, presented as mean6 s.e.m. normalized to b-actin gene expression
(n5 5). *, P, 0.05; **, P, 0.01, one-tailed Mann–Whitney test. b, Top, 59
End of p53 locus. Bottom, Representative analysis from triplicate ChIP analyses
of CHD7 binding to the p53 promoter (P1) and to negative control open-
chromatin regions (P2 and P3), relative to input6 s.d. of technical triplicates.
kb, kilobases. c, Bottom, p53 immunoblot of human fibroblasts derived from
patients with CHARGE syndrome and unaffected individuals (control). The
numbers indicate the p53 levels after normalization to b-actin. Top, Data
are presented as mean6 s.d. of p53 levels. *, P5 0.015, one-tailed Student’s
t-test. d, p53 target gene expression in low-serum treated human fibroblasts
derived from patients with CHARGE syndrome and unaffected individuals
relative to untreated samples. Five CHARGE cell lines were analysed in
duplicate. A representative cell line pair is shown, and data are presented as
mean6 s.d. of technical triplicates. e, Left, p53 immunohistochemistry on
thymi from fetuses with CHARGE syndrome and unaffected fetuses. Arrows
denote p53-positive cells. Right, The number of p53-positive cells per ten
fields at 4003 magnification, from one section; n5 3. *, P5 0.037, one-tailed
Student’s t-test. f, Comparison of Chd72/2p531/2 embryos with control
and Chd72/2p531/1 embryos reveals partial rescue of E10.5 Chd72/2p531/2
embryos (Chd72/2p531/1, n5 3; Chd72/2p531/2, n5 6). Original
magnification, 320. g, Embryo somite number for each genotype.
**, P5 0.0024; ***, P5 0.00032; NS, not significant; two-tailed
Student’s t-test.
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activated in response to other genetic alterations found in CHARGE
syndrome, or components of the p53 pathway could themselves bemu-
tated in someCHARGE cases. Our sequencing analysis of the p53 cod-
ing region in 25CHD7-mutation-negativepatientswithCHARGEfailed
to reveal anymutations, potentially becausemodest p53 activationmay
be difficult to achieve through point mutation, suggesting that muta-
tions inp53 cis-regulatory regionsorpathway componentsmaybemore
likely. Significantly, p53 may act as a common node for developmental
defects not only inCHARGE syndromebut also inother developmental
syndromes, such as 22q11.2 deletion syndrome29. Indeed, p53 activa-
tion by ribosome dysfunction inducesNCCdeficiency and craniofacial
defects30. Future studies will reveal precisely how p53 contributes to
CHARGE syndrome and potentially the broader spectrum of human
craniofacial and cardiac developmental syndromes.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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METHODS
Mouse breeding and analysis. Conditional p53 mutant mice were described
previously3,5. p53LSL-mut/1maleswere crossed toCMV-Cre females, and timedpreg-
nancieswere conducted31. Genotyping analysiswas performedusing yolk sacDNA.
Males were identified using the PCR for the Y-chromosome-specific Zfy gene. As
reported31, we observed mosaic Cre activity in some embryos, reflected by incom-
plete or no lox–Stop–lox deletion in PCR analysis of yolk sacs and in p53 immuno-
histochemical analysis in embryos. Embryos that showed little tono recombination
of the lox–Stop–lox allele were kept separate for all analyses. In the text and figure
labels, the Cre nomenclature for both control and p5325,26,53,54/1 embryos is ex-
cluded for simplicity. The genotypes of p5325,26,53,54/1 mice carrying a CMV-Cre
transgene lack theLSLdesignationbecause the lox–Stop–lox elementhas beendeleted
from the genome. Controls in analyses comprise littermate embryos both with and
without theCMV-Cre transgene (ExtendedData Fig. 3).Miceweremaintained on
a mixed 129/Sv; C57BL/6J background. Chd7-deficient gene-trapped mice were
described previously21. Controls for embryo somite number rescue analysis com-
prised Chd71/1p531/1, Chd71/1p531/2, Chd71/2p531/1 and Chd71/2p531/2
embryos. Sample sizes were estimated, based on previous embryogenesis work, to
be able to reach significant conclusions. For example, using a chi-squared test, we
can estimate that 24 embryos are required to obtain a significance level of 5% if all
homozygous embryos were non-viable and from a heterozygous mating where
homozygotes should represent 25% of the total based onMendelian ratio. All ani-
mal work was done in accordance with the Stanford University APLAC.
Embryo tissue analysis. Embryos were examined under a dissecting microscope
for the presence of a heartbeat and for other abnormalities, in a blinded fashion,
before genotyping, and images of either fixed or live embryos were acquired using
thedissectingmicroscope.Whethermicewere alivewasdeterminedby the presence
of a heartbeat. All analyses were performed on embryos of specified ages as deter-
mined by the expected stage of tissue and organ development in control embryos.
Within age groups, embryoswere randomly assigned for the analysis of individual
tissues. Heart, inner ear and craniofacial analyses were performed with the assist-
ance of collaborators whowere blinded to the genotypes. Histological analysis was
performedonhaematoxylin and eosin stained paraffin-embedded sagittal, coronal
or transverse embryo sections using standard protocols. Consecutive 7-mm sec-
tions were evaluated for heart and craniofacial analyses.Whole-mount images for
craniofacial analysiswere createdby staining embryos in 70%ethanolwith ethidium
bromide and imaging with ultraviolet radiation. Whole-mount cleaved caspase 3
(CC3) staining was performed as described previously32 with anti-CC3 antibody
(Cell SignalingTechnology, 9664), and embryoswere developedwith diaminoben-
zidine (DAB) (Vector Labs). Immunohistochemistry and immunofluorescencewere
performed as describedwith anti-CC3 antibody, anti-5-bromodeoxyuridine (BrdU)
antibody (BD Bioscience, 347580), anti-p53 antibody (Vector Labs, CM5), anti-
PAX3 antibody (IowaDevelopmental StudiesHybridomaBank) and human anti-
p53 antibody (Santa Cruz Biotechnology, Ab1801) on paraformaldehyde-fixed,
paraffin-embedded tissue, and slides were developed with either DAB or imaged
by immunofluorescencemicroscopy. For BrdU staining, the embryos were pulsed
before dissection for 20minwith 0.1mgBrdUper g bodyweight. CC3- andBrdU-
positive cellswere quantified andnormalized to the area, number of sections or total
cell number. Bone and cartilage stainingwere performed as described previously33,
using Alizarin red and Alcian blue to stain bone and cartilage, respectively. Bone
lengths were quantified from measurements on photomicrographs acquired at
6.33magnification. The areas of the kidney and thymuswere calculated frommea-
surements on photomicrographs acquired at 2003 magnification. Inner ear ana-
lysis using the paint-fill assay was performed as described previously34; paint-filled
ears were imaged in brightfield using a Leica DMRB stereoscope. All individuals
with affected ears that could be scored for both ears exhibited a similar severity of
the defect in both ears. Additionally, while different types of analysis precluded
investigation of all phenotypes in particular embryos, defects commonly occurred
in combination: for example, coloboma and inner ear defects occurred together in
57% of p5325,26,53,54/1 embryos examined.
qRT–PCR. For qRT–PCR, MEFs were cultured at subconfluency; RNA was iso-
lated by TRIzol extraction and reverse transcribed using M-MLV Reverse Tran-
scriptase (Invitrogen) and random primers; and PCR was performed in triplicate
using the SYBRGreen system (QIAGENandBio-Rad) andmouse-specific primers
for eachgene (SupplementaryMethodsTable 1a) in a 7900HTFastReal-TimePCR
machine (Applied Biosystems). The results were computed relative to a standard
curvemadewith cDNApooled fromall samples3.Human fibroblastswere cultured
at subconfluency in DMEM with 20% serum or 0.1% serum for 24h before RNA
isolation by TRIzol extraction, and qRT–PCR was performed as above using the
SYBR Green system and human-specific primers for each gene (Supplementary
Methods Table 1b).
Cell culture,westernblot analysis and immunoprecipitation.MEFswere derived
from E13.5 embryos. For stable overexpressingMEF lines, wild-type and p53-null
MEFs were transduced with pWZL-based retroviruses expressing Flag–p53, Flag–
p5325,26,53,54 or empty vector as described previously5.Mutant p53 constructs were
made via site-directed mutagenesis to bear Leu25Gln, Trp26Ser, Phe53Gln and
Phe54Ser mutations, which were found to incapacitate p53’s transactivation cap-
ability. In summary, a p53 cDNA, generated fromMEF RNA, was amplified and
engineered with AscI and PacI restriction enzyme sites using primers against the
secondamino acid through the stop codon (59-TTAGGCGCGCCACTGCCATGG
AGGAGTC-39 and59-GGCGTTAATTAATCAGTCTGAGTCAGGCCCCAC-39).
The amplified DNAwas subcloned into a pBluescript construct with the multiple
cloning site replaced with AscI and PacI sites. The p53 cDNA underwent site-
directedmutagenesis (TTATGG toCAATCG andTTTTTT toCAGTCT) to gen-
erate the four mutations. The mutated p53 cDNA was confirmed by sequencing
and subcloned into the appropriate expression vectors (pWZL or pcDNA) that
contained three copies of either the HA or Flag tag at the amino terminus, as well
as AscI and PacI sites instead of the multiple cloning sites. For western blot anal-
ysis, cells were left untreated, treated with 0.2mgml21 doxorubicin (Dox) for 8 h
or transfected using X-tremeGENE HP (Roche) for 24 h with pcDNA constructs
(Flag–p53, Flag–p5325,26,53,54, HA–p53 or empty vector). Cells were collected and
lysed using RIPA buffer. Western blots were probed with anti-p53 (Vector Labs,
CM5, 1:500), anti-wild-type p53 (provided byD. Lane andB.Vojtesek, pAB242)35,
anti-Flag (Sigma, F3165, 1:1,000), anti-HA (Sigma, H6908, 1:1,000) and anti-actin
(Sigma,A2228, 1:30,000) antibodies. ImmunoprecipitationwasperformedonMEFs
transfectedwith pcDNAconstructs (Flag–p53, Flag–p5325,26,53,54, HA–p53, Flag–
eGFPorHA–MBP) usingM2anti-Flag agarose beads (Sigma,A2220).Dox-treated
p531/2 (Fig. 3a, lane 6) and p5325,26,53,54/2 (Fig. 3a, lane 4) MEFs controlled for
wild-type p53-specific antibody activity and specificity, respectively. Cells were
lysed usingRIPAbuffer; lysateswere added to anti-Flag beads to allow the binding
of Flag protein; and bound protein was retrieved by the addition of sample buffer
and the centrifugation of beads. Ten per cent input was used forwestern blot anal-
ysis. Human fibroblasts were grown in DMEM with 20% serum, and were lysed
using RIPA buffer or were incubated in 0.1% serum for 24 h before collection for
RNA analysis.Western blots were probedwith anti-p53 antibody (SantaCruz Bio-
technology,DO-1). The differentiationofmouseChd71/1 andChd72/2 (whi/whi)
embryonic stemcells intoNCCswasperformedusing an adaptationof a previously
described protocol18,19 that has been further characterized36. Importantly, loss of
CHD7 function does not affect the induction of NCCs, allowing for generation of
the cells for this analysis18. Validation of NCC phenotype was performed by asses-
sing the gene expression of the NCCmarkersWnt1, Snai1 and Pax3 (Supplemen-
tary Methods Table 1a).
ChIP.Analysis of p53 bindingwas performedonMEFs of different genotypes. For
ChIP, 30–403 107 cells were collected, and immunoprecipitation was conducted
using anti-p53 antibody (Vector Labs,CM5), as previously described37. Inbrief, the
cellswere crosslinked following trypsinizationwith1%formaldehydeandquenched
withglycine.Chromatinwas shearedusingaBioruptor sonicator (Diagenode), then
immunoprecipitatedwithanti-p53–Dynabeadsovernight. ImmunoprecipitatedDNA
waswashed, reverse-crosslinked and isolated using a PCR clean-up kit (QIAGEN).
ImmunoprecipitatedDNAwas analysed using qRT–PCRwith binding-site-specific
primers (SupplementaryMethodsTable 2) andnormalized to input.Analysis of p53
binding-site affinitieswas based onpreviously reportedChIP-sequencing data and
a p53 binding-site algorithm17,37. Analysis of CHD7 binding was performed using
anti-CHD7 antibody onNCC-like cells differentiated fromwild-type orChd7-null
(whi/whi) embryonic stem cells using the same protocol as above18.
Human samples.All humanwork was conducted under human subject protocols
approvedby the Stanford Institutional ReviewBoard (IRB), theUniversity ofMich-
iganUM-IRBMED and the Ethical Committee of d’Ile de France II (Nu 2009-164).
Informed consent was obtained from participants in the study. Human fibroblasts
were obtained by skin biopsy under local anaesthesia fromCHARGE patients with
CHD7mutations and unaffected individuals. Thymi were obtained from pregnan-
cies terminated for severemalformations, in accordancewith French law, after genet-
ic counselling, between 24 and 37 weeks of gestation. Detailed clinicopathological
examination allowed the diagnosis of CHARGE syndrome, which was confirmed
by CHD7molecular analysis that identified a de novo nonsense mutation in each
sample.Age-matched control thymiwere obtained from fetuseswith isolatedbrain
malformations.
TP53 (p53) exome sequence was analysed in a group of 25 CHD7-mutation-
negative patients with features of CHARGE syndrome, who were selected in the
cohort based on the availability of parental DNA for segregation analysis, in case a
variantwas found.AllTP53 coding exonswere analysedbydirect sequencingofPCR
products comprising the ten codingexons and theadjacent intronic junctionsofTP53
isoform2 (exons 2 to11, reference sequenceNM_001126112.2) and the alternatively
spliced exon 10 of isoforms 3 and 4 (reference sequences NM_001126114.2 and
NM_001126113.2). This analysis failed to reveal anymutations within the coding
RESEARCH LETTER
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region (that is, no sequence changes apart from already known single nucleotide
polymorphisms).
Statistical analysis.The statistical tests usedwere Student’s t-test (equal variance),
Welch’s t-test (unequal variance), the Mann–Whitney test (non-parametric test)
and the binomial distribution test. Owing to the presence of embryos with little or
no recombinationof the lox–Stop–lox allele, binomial distributionanalysiswasused
to exclude these embryos and to determine the statistical significance for the via-
bility of p5325,26,53,54/1 embryos at each embryonic time point. Additional statist-
ical analyses, with the assistance of the Stanford Biostatistics Core, were performed
to assess viability overmultiple embryonic time points ofCMV-Cre; p5325,26,53,54/1
embryos that had recombined versus those that had not recombined, as scored by
PCR analysis (Extended Data Table 2).
The number of dead p5325,26,53,54/1 embryos, as a proportion of the total (dead
plus alive), was also analysed using logistic regression, with a factor for genotype
and a factor for gestational age. Because some of the totals were small, we assessed
significance using a permutation test, comparing the observed phenotype (the ratio
of dead embryos) to a set of 10,000 random permutations of the phenotype (keep-
ing the number of dead embryos and the total numbers unchanged at each time
point and re-fitting the logistic regression). Note that this analysis assumes the
effect of clustering within dams is negligible. The P value for the permutation test
was 0.0234: 234 out of 10,000 randompermutations showed a greater frequency of
death in absolute value than the frequency of death observed for p5325,26,53,54/1
embryos; the P value from logistic regression software was P5 0.0003. A model
allowing a continuous effect of gestational age was also fitted to explore whether
the genotype affected the rate of change in the hazardof death: the slopes over time
for p5325,26,53,54/1 and control embryos were significantly different (P5 0.0245),
despite the confidence intervals at each individual time point being wide and
overlapping.
31. Schwenk, F., Baron, U. & Rajewsky, K. A cre-transgenic mouse strain for the
ubiquitous deletion of loxP-flanked gene segments including deletion in germ
cells. Nucleic Acids Res. 23, 5080–5081 (1995).
32. Sato, T. & Bartunkova, S. Analysis of embryonic vascular morphogenesis.
Methods Mol. Biol. 137, 223–233 (2000).
33. Ovchinnikov, D. Alcian blue/alizarin red staining of cartilage and bone inmouse.
Cold Spring Harb. Protoc. http://dx.doi.org/10.1101/pdb.prot5170 (March
2009).
34. Hurd, E. A., Poucher, H. K., Cheng, K., Raphael, Y. & Martin, D. M. The ATP-
dependent chromatin remodeling enzyme CHD7 regulates pro-neural gene
expression and neurogenesis in the inner ear. Development 137, 3139–3150
(2010).
35. Lane, D. et al. Epitope analysis of the murine p53 tumour suppressor protein.
Oncogene 12, 2461–2466 (1996).
36. Rada-Iglesias, A. et al. Epigenomic annotation of enhancers predicts
transcriptional regulators of human neural crest. Cell Stem Cell 11, 633–648
(2012).
37. Kenzelmann Broz, D. et al. Global genomic profiling reveals an extensive p53-
regulated autophagyprogramcontributing tokeyp53 responses.GenesDev.27,
1016–1031 (2013).
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Extended Data Figure 1 | Model for examining p53-associated
developmental phenotypes. a, Schematic of p5325,26, p5353,54 and p5325,26,53,54
mutant p53 proteins. Basic, basic-residue-rich domain; PRD, proline-rich
domain; TAD, transcriptional activation domain 1 or 2; Tet, tetramerization
domain. b, p53LSL-mut/1 mice (where mut can denote any of the p53 TAD
mutants) were crossed to p531/1; CMV-Cremice, which express Cre in the
germline, to assess the viability and developmental phenotypes of the p53-
mutant-expressing progeny. c, Table summarizing the actual genotypes and
ultimate functional genotypes of progeny from crosses of p53LSL-25,26,53,54/1 and
p531/2; CMV-Cre mice, as used throughout the manuscript. While
p53LSL-25,26,53,54/1; CMV-Cre is the actual initial genotype, when Cre acts
to delete the lox–Stop–lox (LSL) cassette, the genotype is written as
p5325,26,53,54/1 to reflect this recombination. In the text and figure labels, theCre
nomenclature for both control and p5325,26,53,54/1 embryos is excluded for
simplicity. Controls for analyses comprised embryos both with andwithout the
CMV-Cre transgene, as summarized in Extended Data Fig. 3.
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Extended Data Figure 2 | p5325,26,53,54/2 mice, but not p5325,26/1 or
p5325,26/2mice, are viable. a, Crosses of p53LSL-25,26/1 with p531/1; CMV-Cre
or p531/2; CMV-Cremice revealed a decrease in viable pups expressing
p5325,26 at E9.5–E10.5. The observed numbers of live and dead pups compared
with the expected numbers of live pups are indicated: [Observed (Expected)].
The genotypes of the p5325,26/1 and p5325,26/2 mice carrying a CMV-Cre
transgene lack the LSL designation because the lox–Stop–lox element has been
deleted from the genome. Significance was assessed by binomial distribution
statistical tests on live pups: P5 0.18 for the p531/1 cross and 0.09 for the
p531/2 cross. b, Crosses of p53LSL-25,26/1 or p53LSL-25,26,53,54/1 with
p531/2; CMV-Cre mice revealed that p5325,26,53,54/2 mice, but not p5325,26/2
mice, are viable, as assessed at postnatal day 21 (P21). mut denotes either
mutant allele. The observed numbers of pups are indicated and compared with
the expected numbers of pups: [Observed (Expected)]. The genotypes of
p53mut/1 and p53mut/2 mice carrying a CMV-Cre transgene lack the LSL
designation because the lox–Stop–lox element has been deleted from the
genome. The lack of pups is significant at P21 as assessed by binomial
distribution statistical tests on live pups comparedwith expected: p5325,26/1 and
p5325,26/2, * P5 3.423 1025; p5325,26,53,54/1, ** P5 4.773 1027. c, Whole-
mount images of a p5325,26/1 embryo (right) at E9.5, displaying developmental
delay (top) and neural tube defects, including exencephaly and kinked spine
(bottom), compared with a littermate control (left). Original magnification,
350. d, p5325,26,53,54/2 mice displayed a shorter lifespan (median lifespan, 128
days; n5 8) than wild-type mice (median lifespan, 774 days) and a similar
lifespan to p532/2 mice (median lifespan, 143 days), further indicating that the
p5325,26,53,54 allele itself behaves like a p53-null allele; P, 0.0001 by Mantel–
Cox statistical analysis comparing wild-type and p5325,26,53,54/2 mice.
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Extended Data Figure 3 | Genotypes of the control embryos in the figures
and the genders associated with phenotypes. a, Table identifying the
genotypes of the control embryos shown for each analysis. b, Table showing the
number of male and female p5325,26,53,54/1 embryos observed for the indicated
phenotypes, as assessed by Zfy PCR. The phenotypes are well represented in
both sexes.
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Extended Data Figure 4 | p5325,26,53,54/1 embryos exhibit additional
features of CHARGE syndrome. a, Haematoxylin and eosin stained sections
of E12.5 control (left) and p5325,26,53,54/1 embryos (right). Examination
confirmed neural tube closure defects (arrow). Original magnification, 310.
b, Close-up image of an ultraviolet-radiation-illuminated, ethidium bromide
stained E15.5 p5325,26,53,54/1 embryo (right), highlighting the short lower jaw
phenotype with protruding tongue (arrow) compared with control littermates
(left). Seventy-four per cent of p5325,26,53,54/1 embryos (n5 27) exhibited a
short lower jaw. Cleft lip is not shown. Original magnification, 340. c, Top,
Alizarin red (bone) andAlcian blue (cartilage) stainedwholemount of an E15.0
p5325,26,53,54/1 embryo (right), showing reduced bone density in the cranium
(c), nasal cavity (n), shorter ulna (u), humerus (h), mandible (m) and femur (f),
as well as reduced bone formation in the ribs (R), where fewer vertebrae are
undergoing ossification than in littermate controls (left). The number of
vertebrae with bone formation was 19 in the controls (arrow; V19) and 18 in
p5325,26,53,54/1 embryos (arrow; V18). The severity of the bone and cartilage
defects was variable, with the most severe defects evident in embryos with
exencephaly and severe craniofacial defects (n5 7). Bottom, Quantification of
bone lengths shown as percentage of E14.5–15.0 littermate controls. The bone
lengths of the mandible, humerus, ulna and femur were measured using the
ruler function in Adobe Photoshop on images acquired at 6.33 magnification.
Only litters with detectable bone formation in p5325,26,53,54/1 embryos were
included in bone length analyses: Student’s t-test; **, P5 0.008 (mandible);
**, P5 0.005 (humerus). d, Representative images of haematoxylin and eosin
stained sagittal sections of E12.5 control hearts (left) and p5325,26,53,54/1 hearts
(right), showing all three cardiac cell types in both genotypes. en, endocardium;
ep, epicardium; myo, myocardium (arrows). Original magnification, 3200.
e, A haematoxylin and eosin stained E12.5 p5325,26,53,54/1 heart exhibiting
persistent truncus arteriosus (PTA) (33%, n5 6). The cardiac outflow tract in
the control embryo (left) is septated into the aorta (Ao) and main pulmonary
artery (MPA), whereas the cardiac outflow tract (truncus arteriosus (TA)) in
the p5325,26,53,54/1 embryo (right) remains unseptated, resulting in PTA.
Original magnification, 3100. f, Illustration of a control heart (left) and a
p5325,26,53,54/1 embryo heart (right), highlighting double outlet right ventricle
(DORV) and atrioventricular cushion defects. Both the aorta (Ao) and the
MPA flow out of the right ventricle (RV), resulting in mixed oxygenated and
deoxygenated blood in the systemic circulation when combined with
concurrent ventricular septal defects (VSDs). The atrioventricular cushions
remain bulbous and fail to elongate into mature valve leaflets. Red denotes
oxygenated blood; blue denotes deoxygenated blood; and purple (pink) denotes
mixed oxygenated and deoxygenated blood. mv, mitral valve; tv, tricuspid
valve. Original magnification,3100. g, Representative haematoxylin and eosin
stained transverse section of thymus from a p5325,26,53,54/1 E15.5 embryo
(right) reveals a smaller thymus than in littermate controls (left) (63% of
controls;n5 4). Originalmagnification,3200. h, Representative haematoxylin
and eosin analysis of liver sections from E12.5 controls (left) and p5325,26,53,54/1
embryos (right), showing normal liver architecture in both genotypes (top).
Highmagnification image (bottom) of the region of the liver that is outlined by
the white box in the top panel shows the presence of nucleated erythrocytes
(arrows), indicating proper haematopoiesis. Original magnification top,
3100; bottom,3400. i, Top, Table summarizing the incidence (%) and sample
size (n) of phenotypes assessed qualitatively in p5325,26,53,54/1 embryos. The
occurrence of these phenotypes in CHARGE syndrome is also indicated
(1, present; 2, absent). Bottom, Table summarizing the phenotypes assessed
quantitatively in p5325,26,53,54/1 embryos relative to controls, shown as the
percentage average size of the control (%), with sample size (n) also indicated.
The occurrence of these phenotypes in CHARGE syndrome is also shown
(1, present). A detailed description of the bone and cartilage defects is
provided in c.
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Extended Data Figure 5 | p532/2 embryos do not exhibit characteristics of
CHARGE syndrome. a, Whole-mount image of the external ear of an E15.5
p532/2 embryo (right) and a control embryo (left), showing normal ear
pinna development. Original magnification, 3100. b, Whole-mount image of
an E13.5 p532/2 embryo (right) and a control embryo (left), showing normal
retinal development and no evidence of coloboma. Original magnification,
3100. c, Whole-mount image of an E15.5 p532/2embryo (right) and a control
embryo (left), showing normal lower jaw development. Originalmagnification,
340. d, Top, Alizarin red (bone) and Alcian blue (cartilage) stained whole-
mount E14.5 p532/2embryo (right), showing normal long bone formation of
the ulna (u), humerus (h), mandible (m), and femur (f) relative to littermate
controls (left). Bottom, Quantification of the bone lengths shown as a
percentage of E14.5 littermate controls (n5 3). Original magnification, 36.3.
e, Representative images of haematoxylin and eosin stained sagittal sections of
E13.5 control hearts (left) and p532/2 hearts (right), showing all three cardiac
cell types in both genotypes. en, endocardium; ep, epicardium; myo,
myocardium (arrows). Original magnification, 3200. f, Analysis of
haematoxylin and eosin stained transverse sections of E13.5 p532/2 and
control hearts revealing normal outflow tract development. Top, TheMPAand
Ao are fully septated, and the MPA connects to the right ventricle (RV) in
p532/2 hearts. Bottom, The Ao connects to the left ventricle (LV). The symbol
Wdenotes that the ventricular outflow tract connects theLVandAO.AV, aortic
valve; PV, pulmonary valve. Original magnification, 3100. g, Analysis of
transverse sections of haematoxylin and eosin stained E13.5 p532/2 hearts
(right) reveals normal atrioventricular cushions, which have undergone
remodelling to form mature, elongated mitral valves (mv; arrowhead) and
tricuspid valves (tv; arrow) similar to in control hearts (left). LA, left atrium;
RA, right atrium. Original magnification, 3100. h, Haematoxylin and eosin
stained sagittal section of kidney from p532/2 (right) and control (left)
embryos, showing normal renal size and development. Original magnification,
3200. i, Haematoxylin and eosin stained transverse section of thymus in a
p532/2 E13.5 embryo (right) reveals a similar thymus size to that in a littermate
control (left). Original magnification, 3200.
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Extended Data Figure 6 | p5325,26,53,54/1 embryo tissues display increased
apoptosis and decreased proliferation. a, Left, Immunofluorescence for
phospho-histone H3 (red) in the retina of E13.5 control and p5325,26,53,54/1
embryos. Right, Quantification of phospho-H3-positive cells per retina area
relative to littermate controls. **, P5 0.006 by one-tailed Welch’s t-test
(n5 4). Original magnification, 3200. b, Left, Immunohistochemistry for
cleaved caspase 3 (CC3) in thymi of control (left) and p5325,26,53,54/1 (right)
embryos. Inset, Magnified image of CC3-positive region. Right, Quantification
of CC3-positive cells per thymic area. *, P5 0.02 by one-tailed Student’s t-test
(n5 4). Original magnification, 3400. c, Immunofluorescence for PAX3
(green) in NCCs of E9.5 control and p5325,26,53,54/1 embryos was used to
identify NCCs in Fig. 2f. Original magnification, 3200. d, Left,
Immunofluorescence for CC3 (red) and PAX3 (green) in NCCs of E9.5 control
and p5325,26,53,54/1 embryos. p5325,26,53,54/1 embryos havemore apoptotic (red)
NCCs, as determined by PAX3-positive staining (green), than littermate
controls. Right, Quantification of CC3-positive cells per total NCC number.
P5 0.14 by one-tailed Student’s t-test (n5 4). Original magnification, 3200.
e, Left, Immunofluorescence for CC3 (red) in the otic vesicles of E9.5 control
and p5325,26,53,54/1 embryos. Right, Quantification of CC3-positive cells per
total cell number. *, P5 0.03 by one-tailed Student’s t-test (n5 3). Original
magnification, 3200. f, CC3 staining in whole-mount E8.5 control and
p5325,26,53,54/1 embryos reveals enhanced apoptosis in the neuroepithelium
of p5325,26,53,54/1 embryos (right) but not in controls (left). The close-up shows
a magnification of the caudal neuroepithelium (bottom). Arrows indicate
CC3-positive regions. Original magnification top, 350.
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ExtendedData Figure 7 | p5325,26,53,54 is transactivation dead but augments
wild-type p53 activity. a, Western blot analysis of p53 protein levels in
untreated or doxorubicin-treated (0.2mgml21 Dox) p532/2, p531/2,
p5325,26,53,54/2 and p5325,26,53,54/1 MEFs. b-Actin served as a loading control.
b, Western blot analysis of anti-Flag immunoprecipitation from p532/2
MEFs transiently overexpressing HA–p53 and Flag–p53 or Flag–p5325,26,53,54.
HA–MBP and Flag–eGFPwere used as negative controls. Immunoprecipitated
protein and10% inputwere probedwith either anti-HAor anti-Flag antibodies.
(The microgram ratio of HA–p53 to Flag–p53 or Flag–p5325,26,53,54 plasmid
DNA was 1:1 or 1:2.5, as indicated above the blot (see Fig. 3b). c, Heat map
examining the transactivation capacity of p5325,26,53,54 on p53-dependent genes
identified by microarray analysis through comparison of six HrasV12;
WT p53 MEF lines with six HrasV12; p53-null MEF lines, as previously
described3. Three independentHrasV12; p5325,26,53,54/25,26,53,54MEF lines were
analysed, and the gene expression profiles were indistinguishable from those of
HrasV12; p53-null cells. The numbered columns indicate independent MEF
lines. Blue denotes repressed genes, and red denotes induced genes. d, qRT–
PCR analysis of p53 target gene expression in untreated MEFs derived from
p531/1 and p5325,26,53,54/1 E13.5 embryos. Graphs indicate the mean6 s.d.
from four independent MEF lines after normalization to b-actin gene
expression. **, P, 0.01; ***, P, 0.005; Student’s t-test. e, qRT–PCR analysis
of p53 target gene expression in p531/1 and p532/2 MEFs stably transduced
with empty vector, Flag–p53 or Flag–p5325,26,53,54. The representative gene
expression from one experiment is shown: mean6 s.d. of technical triplicates
after normalization to b-actin gene expression. The experiment was
performed in duplicate.
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Extended Data Figure 8 | p53 heterozygosity partially rescues Chd7-null
embryos. a, qRT–PCR analysis ofChd7 expression in untreatedMEFs derived
from E13.5 p531/2 and p5325,26,53,54/1 embryos. The graphs indicate the
mean6 s.d. from four independent MEF lines after normalization to b-actin
gene expression. ns, not significant. b, Left, Schematic of NCC differentiation.
Right, Representative qRT–PCR analysis of NCC markers in NCC-like
cells differentiated from Chd71/1 and Chd72/2 (whi/whi) mouse embryonic
stem cells normalized to b-actin gene expression and relative to matched
embryonic stem cells. c, Haematoxylin and eosin stained E10.5
Chd71/1p531/2 (control), Chd72/2p531/1 and Chd72/2p531/2 embryos.
The Chd72/2p531/1 embryo shown is necrotic, as evidenced by cellular
autolysis. Original magnification, 332. d, Close-up image of heart region
denoted by red box in panel c, in E10.5 Chd71/1p531/2 (control) and
Chd72/2p531/2 embryos. Original magnification, 3100.
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Extended Data Table 1 | p5325,26,53,54/1mice do not survive to weaning
Crosses of p53LSL-wt/1, p53LSL-53,54/1 or p53LSL-25,26,53,54/1 with p531/1; CMV-Cremice yield the expected numbers of p53wt/1 and p5353,54/1 pups but not p5325,26,53,54/1 pups at postnatal day 21 (P21).
X denotes wild-type or mutant allele. The observed numbers of live and dead pups compared with the expected numbers of live pups are indicated: [Observed (Expected)]. p5353,54 mutations in the second TAD
did not perturb the transcriptional activity of p53 at the genome-wide level and provide a control for the mutation of only these residues. The presence of viable p53wt/1 and p5353,54/1 pups suggests that re-
expression of p53 in early development using this system does not cause developmental defects. The binomial distribution statistical test shows that the absence of p5325,26,53,54/1 pups at P21 is significant.
*, P57.65 310218.
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Extended Data Table 2 | p5325,26,53,54/1 embryo survival and incidence of exencephaly in live embryos
Survival of embryos at E12.5, E13.5, E14.5, E15.5 andE18.5 from timedmatingsbetweenp53LSL-25,26,53,54/1 andp531/1; CMV-Cremice. Thenumbers of livemice of eachgenotypewere identifiedby thepresence
of a heartbeat. The observed numbers of live anddeadpups comparedwith the expectednumbers of live pups are indicated: [Observed (Expected)]. For the p5325,26,53,54/1; Cre genotype, the number of expected
live pups was fewer than for the other genotypes owing to some incidence of incomplete recombination of the LSL element, as detailed below. The number of live embryos exhibiting exencephaly observed at the
time of dissection is also indicated (63%over all time points). Females andmales, as determined by ZfyPCR, exhibited exencephaly with the same frequency. The genotypes of p5325,26,53,54/1 embryos carrying a
CMV-Cre transgene lack the LSL designation because the lox–Stop–lox element has been deleted from the genome. As reported31, we observedmosaic Cre activity in some embryos, reflected by incomplete or no
lox–Stop–lox deletion in PCR analysis of yolk sac DNA. Embryos that showed little to no recombination of the lox–Stop–lox allele were excluded from analyses. Statistical significance for the viability of embryos was
assessed using binomial distribution analysis to account for embryos with little or no recombination of the lox–Stop–lox allele. The binomial distribution statistical test showed that the absence of live
p5325,26,53,54/1 embryos at late-gestational time points is significant. E12.5, P50.290; E13.5, *, P50.019; E14.5, P50.053; E15.5, **, P51.24 31025; E18.5, *, P50.047. Logistic regression to compare the
viability of CMV-Cre; p5325,26,53,54/1 embryos with and without complete recombination showed that the increased death of recombined CMV-Cre; p5325,26,53,54/1 embryos is significant: P,0.0001.
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